Typhoid vaccine study seeks immune clues from healthy volunteers
NCT ID NCT03971669
First seen Mar 30, 2026 · Last updated Jun 14, 2026 · Updated 6 times
Summary
This study aims to learn how the body's immune system responds to the oral typhoid vaccine. Healthy adults aged 18 and older will receive the FDA-approved Vivotif vaccine and provide blood, saliva, and stool samples over up to eight years. The goal is to better understand immune protection that may also apply to other gut infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RISK REDUCTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Maryland, Baltimore, Center for Vaccine Development and Global Health
RECRUITINGBaltimore, Maryland, 21201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.